| Optimal Life Therapy, Llc | |
|
707 Southern Lights Dr Aberdeen MD 21001-1249 | |
| (410) 870-9884 | |
| (410) 670-4046 |
| Full Name | Optimal Life Therapy, Llc |
|---|---|
| Speciality | Community/Behavioral Health |
| Location | 707 Southern Lights Dr, Aberdeen, Maryland |
| Authorized Official Name and Position | Sabrina Bryant (OWNER) |
| Authorized Official Contact | 4109371733 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Optimal Life Therapy, Llc 707 Southern Lights Dr Aberdeen MD 21001-1249 Ph: (410) 937-1733 | Optimal Life Therapy, Llc 707 Southern Lights Dr Aberdeen MD 21001-1249 Ph: (410) 870-9884 |
| NPI Number | 1457063653 |
|---|---|
| Provider Enumeration Date | 12/19/2022 |
| Last Update Date | 12/19/2022 |
| Certification Date | 12/19/2022 |
| Medicare PECOS PAC ID | 1153764337 |
|---|---|
| Medicare Enrollment ID | O20240205001439 |
News Archive
Researchers at the University of Rochester Medical Center have discovered a potentially new approach to deliver therapeutics more effectively to the brain. The research could have implications for the treatment of a wide range of diseases, including Alzheimer's, Parkinson's, ALS, and brain cancer.
VaxInnate Corporation today announced that it has been awarded a contract by the Biomedical Advanced Research and Development Authority, part of the U.S. Department of Health and Human Services, worth up to $196 million to fund the development of recombinant seasonal and pandemic flu vaccines.
The first functional brain mapping facility on the island of Ireland is to be established at the University of Ulster's Magee campus.
Accelr8 Technology Corporation today announced that it completed the sale of a non-exclusive license for its proprietary OptiChem bio-coatings to an innovative, public diagnostics company. The licensee is paying $1,865,000 over four annual escalating payments and intends to use OptiChem® in its disposable diagnostic devices.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite potential safety concerns, Jazz Pharmaceuticals/UCB's sodium oxybate (JZP-6) will account for more than 15 percent of the fibromyalgia drug market in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Sodium oxybate has demonstrated robust efficacy in Phase III clinical trials for fibromyalgia and interviewed thought leaders are impressed with its effect on several key symptom domains of fibromyalgia, which include pain, sleep and fatigue.
› Verified 6 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457063653 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 251S00000X | Community/behavioral Health | (* (Not Available)) | Primary |
| Provider Name | Sabrina Levell Bryant |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1720484900 PECOS PAC ID: 0143528455 Enrollment ID: I20160419001993 |
News Archive
Researchers at the University of Rochester Medical Center have discovered a potentially new approach to deliver therapeutics more effectively to the brain. The research could have implications for the treatment of a wide range of diseases, including Alzheimer's, Parkinson's, ALS, and brain cancer.
VaxInnate Corporation today announced that it has been awarded a contract by the Biomedical Advanced Research and Development Authority, part of the U.S. Department of Health and Human Services, worth up to $196 million to fund the development of recombinant seasonal and pandemic flu vaccines.
The first functional brain mapping facility on the island of Ireland is to be established at the University of Ulster's Magee campus.
Accelr8 Technology Corporation today announced that it completed the sale of a non-exclusive license for its proprietary OptiChem bio-coatings to an innovative, public diagnostics company. The licensee is paying $1,865,000 over four annual escalating payments and intends to use OptiChem® in its disposable diagnostic devices.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite potential safety concerns, Jazz Pharmaceuticals/UCB's sodium oxybate (JZP-6) will account for more than 15 percent of the fibromyalgia drug market in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Sodium oxybate has demonstrated robust efficacy in Phase III clinical trials for fibromyalgia and interviewed thought leaders are impressed with its effect on several key symptom domains of fibromyalgia, which include pain, sleep and fatigue.
› Verified 6 days ago
News Archive
Researchers at the University of Rochester Medical Center have discovered a potentially new approach to deliver therapeutics more effectively to the brain. The research could have implications for the treatment of a wide range of diseases, including Alzheimer's, Parkinson's, ALS, and brain cancer.
VaxInnate Corporation today announced that it has been awarded a contract by the Biomedical Advanced Research and Development Authority, part of the U.S. Department of Health and Human Services, worth up to $196 million to fund the development of recombinant seasonal and pandemic flu vaccines.
The first functional brain mapping facility on the island of Ireland is to be established at the University of Ulster's Magee campus.
Accelr8 Technology Corporation today announced that it completed the sale of a non-exclusive license for its proprietary OptiChem bio-coatings to an innovative, public diagnostics company. The licensee is paying $1,865,000 over four annual escalating payments and intends to use OptiChem® in its disposable diagnostic devices.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite potential safety concerns, Jazz Pharmaceuticals/UCB's sodium oxybate (JZP-6) will account for more than 15 percent of the fibromyalgia drug market in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Sodium oxybate has demonstrated robust efficacy in Phase III clinical trials for fibromyalgia and interviewed thought leaders are impressed with its effect on several key symptom domains of fibromyalgia, which include pain, sleep and fatigue.
› Verified 6 days ago
Nova Wellness Program, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 780 W Bel Air Ave Ste C, Aberdeen, MD 21001 Phone: 833-337-6682 Fax: 410-692-0143 | |
Confidence Health Services Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 219 W Bel Air Ave Ste 6, Aberdeen, MD 21001 Phone: 443-562-6538 | |
Parents On Patrol, Inc. Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 8 Howard St, Aberdeen, MD 21001 Phone: 443-360-5075 | |
Key Point Health Services, Inc. Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 109 W Bel Air Ave, Aberdeen, MD 21001 Phone: 410-272-1808 Fax: 410-272-1943 | |
Mcnolan Healthcare Services Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 1330 N Sewards Ct, Aberdeen, MD 21001 Phone: 646-965-0900 | |
Key Point Health Services, Inc. Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 135 N Parke St, Aberdeen, MD 21001 Phone: 443-625-1588 Fax: 443-625-1595 | |
Progressive Multi Medical Services Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 200 N Philadelphia Blvd Ste A, Aberdeen, MD 21001 Phone: 443-530-3182 Fax: 443-399-8223 |